Phase 2
Completed N=6
Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
Source: ClinicalTrials.gov NCT00594945 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcomePrimary: Number of Spikes and Sharp Waves, Relative Change From Baseline to Treatment Day (%). — -7.4; -26.1 percentage of baseline
Summary
Evaluate the safety and efficacy of intranasal Clonazepam in subjects with epilepsy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Spikes and Sharp Waves, Relative Change From Baseline to Treatment Day (%). |
-7.4; -26.1 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of refractory epilepsy
- No Nasal conditions that would preclude the use of intranasal product
Exclusion Criteria
- Subject with a clinical significant unstable medical abnormality
- Subject currently or regularly taking Clonazepam
Data sourced from ClinicalTrials.gov (NCT00594945). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.